+181.0%
NTRA vs GSK
+39.6%
+141.4%
-72.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -1.6% | +1.7% | +0.3% |
| 7D | -10.2% | -4.7% | -5.5% | -9.7% |
| 30D | -28.6% | -4.7% | -23.9% | -28.2% |
| 3M | -10.8% | -8.8% | -2.1% | -9.8% |
| 6M | +47.9% | -4.6% | +52.5% | +48.4% |
| YTD | +26.6% | +1.0% | +25.6% | +26.1% |
| 1Y | +32.8% | +6.9% | +25.9% | +31.4% |
| 3Y | +441.7% | +52.5% | +389.2% | +409.6% |
| 5Y | +181.0% | +40.3% | +140.7% | +166.6% |
| All | +181.0% | +39.6% | +141.4% | +166.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling